The agonising negative trend in monitoring of clinical trials

Lancet

Volumn 354, Issue 9194, 1999, Pages 1983-1988

  DeMets, David L ^a   Pocock, Stuart J ^a   Julian, Desmond G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATENOLOL; BETA CAROTENE; ENALAPRIL; ENCAINIDE; ESTROGEN; FLECAINIDE ACETATE; FLOSEQUINAN; GESTAGEN; KETANSERIN; MILRINONE; PIPERANOMETOZINE; RETINOL;

ARTICLE; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DECISION MAKING; DRUG EFFECT; DRUG SAFETY; ETHICS; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; MEDICAL RESEARCH; MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICS; THERAPY;

EID: 0033524162     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)03464-9     Document Type: Review

References (30)

1. Organization, review, and administration of cooperative studies (Greenberg Report): a report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Controlled Clin Trials. 9:1988;137-148.
2. Practical aspects of decision making in clinical trials: the Coronary Drug Project as a case study. Controlled Clin Trials. 1:1981;363-376.
3. Fleming T.R., DeMets D.L. Monitoring of clinical trials: issues and recommendations. Controlled Clin Trials. 14:1993;183-197.
4. Schwartz P.J., Julian D.G., Bigger J.T.et al. The early termination of clinical trials: causes, consequences, and control - with special reference to trials in the field of arrhythmias and sudden death. Circulation. 89:1994;2892-2907.
5. Pocock S.J. When to stop a clinical trial. BMJ. 305:1992;235-240.
6. DeMets D.L. Principles of data and safety monitoring boards. Hennekens C.H. Clinical trials in cardiovascular disease. 1999;31-42 WB Saunders, Philadelphia.
7. Peto R., Pike M.C., Armitage P.et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient: I: introduction and design. Br J Cancer. 34:1976;585-612.
8. Pocock S.J. Group sequential methods in the design and analysis of clinical trials. Biometrika. 64:1977;191-199.
9. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics. 35:1979;549-556.
10. DeMets D.L., Lan K.K.G. Interim analyses: the alpha spending function approach. Stat Med. 13:1994;1341-1352.
11. Jennison C., Turnbull B.W. Interim analyses: repeated confidence interval approach. J R Stat Soc. 51:1989;305-361.
12. DeMets D.L., Ware J.H. Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika. 69:1982;661-663.
13. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HR). Lancet. 353:1999;2001-2007.
14. Lan K.K.G., Wittes J. The, B-value: a tool for monitoring data. Biometrics. 44:1988;579-585.
15. Freedman L.S., Spiegelhalter D.J., Parmar M.K.B. The what, why, and how of Bayesian clinical trials monitoring. Stat Med. 13:1994;1371-1383.
16. A randomized trial of propranolol in patients with acute myocardial infarction: I: mortality results. JAMA. 247:1982;1707-1714.
17. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 321:1989;129-135.
18. Swedberg K., Held P., Kjekshus J., Rasmussen K., Ryden L., Wedel H. Effect of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (Consensus II). N Engl J Med. 327:1992;678-684.
19. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 312:1989;406-412.
20. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 327:1992;227-233.
21. Packer M., Carver J.R., Rodehoffer R.J.et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 325:1991;1468-1475.
22. Packer M., Rouleau J., Swedberg K.et al. Effect of flosequinone on survival in chronic heart failure: preliminary results of the PROFILE study. Circulation. 30I:1993;88 (suppl I);405abstr.
23. Cohn J.N., Goldstein S.O., Greenberg B.H.et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med. 339:1998;1810-1816.
24. Feldman A.M., Bristow M.R., Parmley W.W.et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 329:1993;149-155.
25. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 330:1994;1029-1035.
26. Omenn G.S., Goodman G.E., Thornquist M.D.et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 334:1996;1150-1155.
27. Prevention of atherosclerotic complication: controlled trial of ketanserin. BMJ. 298:1989;424-430.
28. Hulley S., Grady D., Bush T.et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 280:1998;605-613.
29. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet. ii:1986;57-66.
30. Yusuf S., Wittes J., Probstfield J., Tyroler H.A. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 266:1991;93-98.